156 related articles for article (PubMed ID: 37592092)
41. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Chuah C; Koh LP; Numbenjapon T; Zang DY; Ong KH; Do YR; Ohkura M; Ono C; Viqueira A; Cortes JE; Brümmendorf TH
Int J Hematol; 2021 Jul; 114(1):65-78. PubMed ID: 33851349
[TBL] [Abstract][Full Text] [Related]
42. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
43. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
[TBL] [Abstract][Full Text] [Related]
45. The role of bosutinib in the treatment of chronic myeloid leukemia.
Gambacorti-Passerini C; le Coutre P; Piazza R
Future Oncol; 2020 Jan; 16(2):4395-4408. PubMed ID: 31833784
[TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
[TBL] [Abstract][Full Text] [Related]
47. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Claudiani S; Janssen JJWM; Byrne J; Smith G; Blijlevens N; Raghavan M; Smith M; Clark RE; Mclain-Smith S; Carter AM; Milojkovic D; Apperley JF
Eur J Haematol; 2022 Jul; 109(1):90-99. PubMed ID: 35403752
[TBL] [Abstract][Full Text] [Related]
48. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Keller-V Amsberg G; Brümmendorf TH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
[TBL] [Abstract][Full Text] [Related]
49. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
50. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Gambacorti-Passerini C; Cortes JE; Lipton JH; Dmoszynska A; Wong RS; Rossiev V; Pavlov D; Gogat Marchant K; Duvillié L; Khattry N; Kantarjian HM; Brümmendorf TH
Am J Hematol; 2014 Oct; 89(10):947-53. PubMed ID: 24944159
[TBL] [Abstract][Full Text] [Related]
51. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
52. A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.
Nakaseko C; Takahashi N; Ishizawa K; Kobayashi Y; Ohashi K; Nakagawa Y; Yamamoto K; Miyamura K; Taniwaki M; Okada M; Kawaguchi T; Shibata A; Fujii Y; Ono C; Ohnishi K
Int J Hematol; 2015 Feb; 101(2):154-64. PubMed ID: 25540064
[TBL] [Abstract][Full Text] [Related]
53. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
Kantarjian HM; Mamolo CM; Gambacorti-Passerini C; Cortes JE; Brümmendorf TH; Su Y; Reisman AL; Shapiro M; Lipton JH
Cancer; 2018 Feb; 124(3):587-595. PubMed ID: 29072772
[TBL] [Abstract][Full Text] [Related]
54. Bosutinib in chronic myeloid leukemia: patient selection and perspectives.
Isfort S; Brümmendorf TH
J Blood Med; 2018; 9():43-50. PubMed ID: 29695943
[TBL] [Abstract][Full Text] [Related]
55. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.
García-Gutiérrez V; Martinez-Trillos A; Lopez Lorenzo JL; Bautista G; Martin Mateos ML; Alvarez-Larrán A; Iglesias Pérez A; Romo Collado A; Fernandez A; Portero A; Cuevas B; Ruiz C; Romero E; Ortega F; Mata I; Tallón J; García Garay Mdel C; Ramirez Sánchez MJ; de Las Heras N; Giraldo P; Bobillo S; Guinea JM; Deben G; Valencia S; Sebrango A; Boqué C; Maestro B; Steegmann JL
Am J Hematol; 2015 May; 90(5):429-33. PubMed ID: 25683327
[TBL] [Abstract][Full Text] [Related]
56. Bosutinib-induced late-onset severe liver injury preceded by eosinophilia.
Watanabe N; Takaku T; Fujioka I; Tsuchiya S; Ando M
Ann Hematol; 2022 Oct; 101(10):2257-2262. PubMed ID: 36002756
[TBL] [Abstract][Full Text] [Related]
57. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
[TBL] [Abstract][Full Text] [Related]
58. Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Mohanavelu P; Mutnick M; Mehra N; White B; Kudrimoti S; Hernandez Kluesner K; Chen X; Nguyen T; Horlander E; Thenot H; Kota V; Mitchell CS
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33915952
[TBL] [Abstract][Full Text] [Related]
59. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
Monestime S; Al Sagheer T; Tadros M
Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
[TBL] [Abstract][Full Text] [Related]
60. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
